Chapter 32 — Case Study 1: Blood Glucose, Diabetes, and HbA1c

"The simplest molecule in your body is the most heavily regulated. Glucose concentration in blood is held within a 3-fold range — 70 to 200 mg/dL across most of life — by the most elaborate hormonal feedback system humans possess. The chemistry that makes this regulation visible (and trackable as a disease marker) is Chapter 32 chemistry." — paraphrase of an endocrinology text

Diabetes mellitus is one of the most prevalent chronic diseases in the world (~10% of the global adult population). Its molecular basis is dysregulation of glucose metabolism. Its clinical management depends on a remarkable chemical marker — HbA1c (glycated hemoglobin) — that reads out the patient's average blood glucose over the past 3 months. The HbA1c chemistry is exactly the imine + Amadori chemistry of Chapter 25 applied to the carbohydrate biology of Chapter 32.

This case study explores diabetes through the lens of carbohydrate chemistry, with particular emphasis on glycation and HbA1c.

Glucose homeostasis

A healthy adult has blood glucose in the range: - Fasting: 70–100 mg/dL (4–6 mM). - Post-meal: up to ~140 mg/dL (~8 mM), returning to fasting in 2 hours. - Bedtime: ~100–125 mg/dL (5.5–7 mM).

This 2- to 3-fold range is held by the interplay of: - Insulin (from pancreatic β-cells): signals cells to take up glucose; signals the liver to store glucose as glycogen. - Glucagon (from pancreatic α-cells): signals the liver to release glucose from glycogen; signals fasting metabolism. - Cortisol, epinephrine, growth hormone: stress and developmental regulation of glucose.

The relevant chemistry: insulin signals via tyrosine kinase receptor; glucose enters cells via GLUT transporters (especially GLUT4 in muscle and adipose); glucose is metabolized via glycolysis (Section 32.10). These are not Chapter 32 chemistry per se, but they regulate glucose's concentration.

Type 1 vs Type 2 diabetes

Diabetes comes in two main forms:

Type 1 diabetes (T1D)

Autoimmune destruction of pancreatic β-cells. Without β-cells, no insulin. Without insulin, glucose cannot enter most cells; blood glucose rises uncontrollably.

• Onset: typically childhood or young adulthood.
• ~10% of all diabetes.
• Treatment: insulin injection or pump.
• Untreated: diabetic ketoacidosis (DKA) within days; death within weeks.

Type 2 diabetes (T2D)

Insulin resistance — cells become less responsive to insulin signaling. The β-cells initially produce more insulin to compensate, but eventually fail. Blood glucose rises gradually.

• Onset: typically adulthood, often associated with obesity and metabolic syndrome.
• ~90% of all diabetes.
• Treatment: lifestyle (diet, exercise) + oral medications (metformin, sulfonylureas, GLP-1 agonists, SGLT2 inhibitors); eventually may need insulin.
• Untreated: gradual organ damage over years.

Both types end up with similarly elevated blood glucose. The chemistry of damage (glycation) is the same.

HbA1c: the chemistry of glycation

Hemoglobin A (HbA) is the major adult hemoglobin. Each Hb molecule has 4 polypeptide chains (2 α + 2 β), each with an N-terminal valine.

When glucose's open-chain aldehyde encounters the N-terminal valine amine of HbA, non-enzymatic glycation occurs. The chemistry is:

1. Schiff base formation (Ch 25): glucose's C1 aldehyde + valine α-amine → imine + water. This step is reversible.

2. Amadori rearrangement: the imine tautomerizes to an enaminol intermediate; the enaminol cyclizes to give a stable 1-amino-1-deoxy-2-keto sugar (a "ketosamine"). This rearrangement is essentially an enol-keto tautomerism (Ch 27). Once Amadori-rearranged, the modification is essentially permanent.

The result: a glucose covalently attached to the N-terminus of hemoglobin via an amine-modified position. This is HbA1c.

The clinical value of HbA1c

HbA1c accumulates over the lifetime of the red blood cell (~120 days). The fraction of HbA1c reflects the average blood glucose over the past 2–3 months:

Conversion formula: avg glucose (mg/dL) ≈ (HbA1c × 28.7) - 46.7.

Diabetes diagnostic thresholds: - < 5.7%: normal. - 5.7–6.4%: prediabetes. - ≥ 6.5%: diabetes.

Treatment targets typically aim for HbA1c < 7% (< 154 mg/dL average), though individualized goals vary.

The HbA1c assay is one of the most-ordered blood tests in the world, with ~1 billion HbA1c tests performed globally per year. The chemistry is Chapter 32 + Chapter 25.

The damage caused by chronic hyperglycemia

Long-term high blood glucose causes "diabetic complications" via several mechanisms, most involving non-enzymatic glycation:

Microvascular complications

• Diabetic retinopathy: glycation of retinal proteins, capillary damage, vision loss.
• Diabetic nephropathy: glycation of kidney proteins, capillary damage, kidney failure.
• Diabetic neuropathy: glycation of nerve proteins, especially myelin sheath; chronic numbness and pain.

Macrovascular complications

• Atherosclerosis: glycation of LDL and other lipoproteins; oxidative stress; plaque formation.
• Coronary artery disease: a major cause of death in long-term diabetics.
• Stroke risk: similarly elevated.

Other

• Wound healing impairment: glycation of structural proteins of the dermis.
• Increased infection risk: glycation impairs immune function.

The chemistry of glycation propagates beyond just HbA1c. Long-lived proteins like collagen accumulate glycation modifications, becoming brittle and dysfunctional. This is why diabetic patients age tissue faster — the molecular damage from glucose chemistry compounds over decades.

Modern diabetes drugs

Several major drug classes treat T2D:

Metformin (a guanidine compound)

The first-line oral diabetes drug. Mechanism: decreases hepatic gluconeogenesis (glucose production by the liver). Mode of action involves AMPK activation but is not fully understood.

Sulfonylureas (e.g., glipizide)

Stimulate β-cell insulin secretion. Older drugs; can cause hypoglycemia.

GLP-1 agonists (e.g., semaglutide / Ozempic, liraglutide / Victoza)

Mimic the natural incretin hormone GLP-1. Enhance insulin secretion in response to food, slow gastric emptying, reduce appetite. Newer GLP-1 agonists are also approved for weight loss (Wegovy = high-dose semaglutide).

These drugs have transformed diabetes (and obesity) treatment in the last decade. Their chemistry is peptide chemistry (Ch 33), not directly carbohydrate chemistry.

SGLT2 inhibitors (e.g., canagliflozin, empagliflozin)

Block glucose reabsorption in the kidney, causing glucose excretion in urine. The kidneys normally reabsorb >99% of filtered glucose; SGLT2 inhibitors reduce this. Result: lower blood glucose; weight loss; some cardiovascular benefit.

The chemistry: SGLT2 is a glucose transporter; the drug is a glucose mimic (a glucoside) that competitively binds SGLT2 without being transported. The drug shape is largely Chapter 32 carbohydrate chemistry.

Insulin and insulin analogs

For T1D and advanced T2D. Recombinant human insulin and various analogs (rapid-acting, long-acting, etc.). Chemistry: peptide chemistry.

Take-home

• Blood glucose is regulated by insulin and glucagon, with a normal range of 70–140 mg/dL.
• Diabetes (T1D, T2D) causes elevated blood glucose, leading to long-term tissue damage.
• The chemistry of damage is glycation: glucose's open-chain aldehyde forms Schiff bases with protein amines (Ch 25), then undergoes Amadori rearrangement (Ch 27 enol/keto chemistry) to give stable ketosamines.
• HbA1c is the canonical glycation marker: glucose + N-terminal valine of hemoglobin → modified protein. HbA1c accumulates over the RBC lifetime (~120 days), giving an average glucose reading.
• HbA1c diagnostic thresholds: < 5.7% normal; 5.7–6.4% prediabetes; ≥ 6.5% diabetes.
• Long-term hyperglycemia damages microvascular (retina, kidney, nerves) and macrovascular (coronary, cerebral) systems.
• Modern diabetes drugs include metformin, GLP-1 agonists (semaglutide), SGLT2 inhibitors, and insulin.
• The chemistry that underlies both the disease and its measurement is Chapter 32 + Chapter 25 + Chapter 27 — the integration of carbohydrate, carbonyl, and α-carbon chemistry.